+

WO2008065144A3 - Galenic formulations of organic compounds - Google Patents

Galenic formulations of organic compounds Download PDF

Info

Publication number
WO2008065144A3
WO2008065144A3 PCT/EP2007/062960 EP2007062960W WO2008065144A3 WO 2008065144 A3 WO2008065144 A3 WO 2008065144A3 EP 2007062960 W EP2007062960 W EP 2007062960W WO 2008065144 A3 WO2008065144 A3 WO 2008065144A3
Authority
WO
WIPO (PCT)
Prior art keywords
organic compounds
galenic formulations
dosage form
present
amount
Prior art date
Application number
PCT/EP2007/062960
Other languages
French (fr)
Other versions
WO2008065144A2 (en
Inventor
Begona Carreno-Gomez
Original Assignee
Novartis Ag
Begona Carreno-Gomez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Begona Carreno-Gomez filed Critical Novartis Ag
Publication of WO2008065144A2 publication Critical patent/WO2008065144A2/en
Publication of WO2008065144A3 publication Critical patent/WO2008065144A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a dosage form for transmucosal administration comprising a therapeutically effective amount of PTH or a pharmaceutically acceptable salt thereof, and an excipient for transmucosal delivery, wherein the active ingredient is present in an amount of 0.001 to 80% by weight based on the total weight of the dosage form.
PCT/EP2007/062960 2006-11-29 2007-11-28 Galenic formulations of organic compounds WO2008065144A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125019 2006-11-29
EP06125019.7 2006-11-29

Publications (2)

Publication Number Publication Date
WO2008065144A2 WO2008065144A2 (en) 2008-06-05
WO2008065144A3 true WO2008065144A3 (en) 2009-03-19

Family

ID=37872188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/062960 WO2008065144A2 (en) 2006-11-29 2007-11-28 Galenic formulations of organic compounds

Country Status (1)

Country Link
WO (1) WO2008065144A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009125432A2 (en) * 2008-04-11 2009-10-15 Lupin Limited Gas empowered expandable drug delivery systems
US9402806B2 (en) * 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
DE102011088909A1 (en) * 2011-08-12 2013-02-14 Labtec Gmbh Process for the preparation and control of oral drug films
EP3568124A1 (en) 2017-01-11 2019-11-20 Ferring B.V. A fast disintegrating pharmaceutical composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578567A (en) * 1990-09-20 1996-11-26 Sandoz Ltd. Nasal pharmaceutical composition
US20050276843A1 (en) * 2004-05-10 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578567A (en) * 1990-09-20 1996-11-26 Sandoz Ltd. Nasal pharmaceutical composition
US20050276843A1 (en) * 2004-05-10 2005-12-15 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MORLEY PAUL: "DELIVERY OF PARATHYROID HORMONE FOR THE TREATMENT OF OSTEOPOROSIS", EXPERT OPINION ON DRUG DELIVERY, ASHLEY PUBLICATIONS, XX, vol. 2, no. 6, November 2005 (2005-11-01), pages 993 - 1002, XP008076969, ISSN: 1742-5247 *

Also Published As

Publication number Publication date
WO2008065144A2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2008023016A3 (en) Galenic formulations of aliskiren
MY148773A (en) Galenic formulations of organic compounds
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
EP1834637A4 (en) Preventive/therapeutic composition for free radical disease
WO2007106550A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
WO2008144269A3 (en) Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
WO2007020204A3 (en) Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
UA96622C2 (en) Solid dosage forms comprising aliskiren obtained by solvent-free granulation process
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2008065144A3 (en) Galenic formulations of organic compounds
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2008062475A3 (en) Pharmaceutical compositions of ursodiol
WO2007011958A3 (en) Intraoral dosage forms of glucagon
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2010003472A3 (en) Lozenge composition for treating inflammatory diseases of the mouth and pharynx
MA32722B1 (en) GALENIC FORMULATION COMPRISING ALISKIRENE AND ASSOCIATED PREPARATION METHOD BY FUSION-EXTRUSION GRANULATION
WO2006008173A3 (en) Pharmaceutical formulations for inhalation
WO2009040373A3 (en) Galenical formulations of aliskiren
WO2003070153A3 (en) Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
WO2008009589A3 (en) Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
WO2005020968A3 (en) Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07847477

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07847477

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载